Product Information
ZORYVE 0.3% FOAM is a brand product labeled by Arcutis Biotherapeutics, Inc., priced at $15.3778 per GM under NDC 80610043060. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Dec 15, 2023.
The High Outlier badge above means this manufacturer's average price in the roflumilast market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3 mg/g
Manufacturer
Arcutis Biotherapeutics, Inc.NDC
80610043060
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
ROFLUMILASTApproval Type
New Drug (NDA)
FDA Application
NDA217242FDA Approved
12/15/2023
On Market Since
12/15/2023
Pharmacological Classes
Price Statistics
The NADAC for ZORYVE 0.3% FOAM has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 12.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.3778 per GM |
|---|---|
| All-time high | $15.3897 (May 13, 2026) |
| All-time low | $13.6685 (Jun 19, 2024) |
| 52-week high | $15.3897 |
| 52-week low | $14.7978 |
| Median price | $14.7981 |
| Average price | $14.7591 |
| Largest weekly change | +4.0% (Jan 7, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the roflumilast market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Arcutis Biotherapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
roflumilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZORYVE 0.3% FOAM?
The current National Average Drug Acquisition Cost (NADAC) for ZORYVE 0.3% FOAM, manufactured by Arcutis Biotherapeutics, Inc., is $15.3778 per GM (NDC 80610043060), effective Sep 30, 2026.
How has the price of ZORYVE 0.3% FOAM changed over time?
Over the history we have for it, the NADAC for ZORYVE 0.3% FOAM has risen 12.1%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ZORYVE 0.3% FOAM?
Since Apr 17, 2024, the NADAC for ZORYVE 0.3% FOAM has ranged from a low of $13.6685 (Jun 19, 2024) to a high of $15.3897 (May 13, 2026), with a median of $14.7981 per GM.
Are there cheaper alternatives to ZORYVE 0.3% FOAM?
No other NADAC-published product currently shares the active ingredient and strength of ZORYVE 0.3% FOAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZORYVE 0.3% FOAM?
ZORYVE 0.3% FOAM (NDC 80610043060) is labeled by Arcutis Biotherapeutics, Inc., and CMS classifies it as a brand product.